News

Timber Pharmaceuticals Appoints Alan Mendelsohn, M.D., as Chief Medical Officer

SmallCaps Daily January 26, 2021

347 3 minutes read

[ad_1]

Dr.
Mendelsohn has 20+ Years’ Experience in Clinical Development and Medical
Affairs

WOODCLIFF LAKE, NJ – (NewMediaWire) – January 25, 2021 – Timber
Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American:
TMBR), a biopharmaceutical company focused on the development and
commercialization of treatments for rare and orphan dermatologic diseases,
today announced the appointment of Alan Mendelsohn, M.D., as Chief Medical
Officer. Dr. Mendelsohn assumes the roles and responsibilities of Amir
Tavakkol, Ph.D., who will be stepping down as the Company’s Chief Scientific
Officer.

“We are pleased to welcome Dr. Mendelsohn to our management team.
Dr. Mendelsohn recently supported the approval and launch of a new treatment
for moderate to severe plaque psoriasis and has a deep understanding of
clinical development and medical commercialization in dermatology,” said John
Koconis, Chief Executive Officer of Timber. “We also thank Dr. Tavakkol for his
support in establishing a strong scientific platform for us to build on as we
advance into clinical stage research.”

Dr. Mendelsohn is a board-certified pediatric cardiologist with
more than 20 years of experience in clinical development and medical affairs.
Prior to joining Timber, he served as Associate Vice president of Dermatology
Medical Affairs for Sun Pharmaceuticals Industries. Previously Dr. Mendelsohn
led the U.S. rheumatology medical affairs team for Pfizer as a Senior Director
and was Senior Director of Immunology Research and Development for Janssen
where he worked
on both rheumatology and dermatology indications. He has also served in various
leadership roles at Centocor, Inc., a Johnson & Johnson company. Dr.
Mendelsohn holds a medical degree from the State University of New York Health
Science Center at Brooklyn.

“This is an exciting time to join Timber as the Company continues
to enroll patients in important studies for underserved dermatologic diseases
including congenital ichthyosis and facial angiofibromas in tuberous sclerosis
complex,” said Dr. Mendelsohn. “I hope to use my experience to help our Timber
team successfully navigate the clinical development process through regulatory
reviews and look forward to serving patients and families living with these
rare conditions. As a former practicing pediatric cardiologist, I have and will
continue to focus my passion on developing treatments for the underserved.”

About Timber Pharmaceuticals, Inc.

Timber
Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development
and commercialization of treatments for rare and orphan dermatologic diseases.
The Company’s investigational therapies have proven mechanisms-of-action backed
by decades of clinical experience and well-established CMC (chemistry,
manufacturing and control) and safety profiles. The Company is initially
focused on developing non-systemic treatments for rare dermatologic diseases
including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous
sclerosis complex (TSC), and scleroderma. For more information, visit www.timberpharma.com.

Forward-Looking Statements

This
press release contains certain forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended,
including those relating to the Company’s product development, clinical and
regulatory timelines, market opportunity, competitive position, intellectual
property rights, possible or assumed future results of operations, business
strategies, potential growth opportunities and other statements that are
predictive in nature. These forward-looking statements are based on current
expectations, estimates, forecasts and projections about the industry and
markets in which we operate and management’s current beliefs and assumptions.

These
statements may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,”
“intend,” “plan,” “believe,”
“estimate,” “potential, “predict,”
“project,” “should,” “would” and similar
expressions and the negatives of those terms. These statements relate to future
events or our financial performance and involve known and unknown risks,
uncertainties, and other factors which may cause actual results, performance or
achievements to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company’s Form 10-Q filed on August 18,
2020 and its other filings with the Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on such
forward-looking statements, which speak only as of the date of this press
release. The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.